JJ Kang, PhD
Dr. Kang joined The Column Group in 2015. Previously, Dr. Kang worked at FibroGen in the project management of drug discovery and development programs, and prior to that, in corporate strategy. Dr. Kang investigated inhibition of DNA methylation and chemical induction of immunogenicity in cancer cells in the laboratory of Professor Peter Dervan, completing her PhD at the California Institute of Technology. Dr. Kang attended Harvard University for her undergraduate studies.
Board of Directors: Escient Pharmaceuticals